Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Hyams

Pediatric Gastroenterology Hartford, CT Medical Doctor

NPI 1215925037 CMS profile 9257

282 Washington St, Hartford, CT 06106

Open in the dashboard

General payments

$76,183

185 records reported · program years 2019–2025

Research payments

$49,756

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,731,816 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jeffrey Hyams of Hartford, CT is reported in the CMS Open Payments database as having received $76,183 across 185 general payments and $49,756 in research payments paid to them. Separately, studies naming them as principal investigator received $1,731,816 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Pediatric Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21,897 54
2024 General $2,840 36
2023 General $8,194 22
2023 Research $1,925 1
2022 General $7,318 15
2021 General $15,950 17
2021 Research $47,748 4
2020 General $2,115 2
2020 Research $83 1
2019 General $17,869 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Hyams
  • Pediatric Gastroenterology median
  • Middle half of Pediatric Gastroenterology
  • National median

In program year 2025, general payments to Jeffrey Hyams were reported at $21,897. Among 1,132 Pediatric Gastroenterology profiles paid that year, the median was $194 and the middle half received between $81 and $540.

Show as a table
Year Jeffrey Hyams Pediatric Gastroenterology median Middle half National median
2019 $17,869 $131 $41–$311 $163
2020 $2,115 $79 $23–$223 $114
2021 $15,950 $104 $32–$321 $132
2022 $7,318 $125 $37–$331 $149
2023 $8,194 $169 $55–$440 $160
2024 $2,840 $196 $73–$563 $164
2025 $21,897 $194 $81–$540 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Scientific Affairs, LLC $21,620 21 payments
  2. Pfizer Inc. $9,800 4 payments
  3. Eli Lilly and Company $8,961 12 payments
  4. AbbVie, Inc. $8,151 78 payments
  5. Genentech, Inc. $8,004 6 payments
  6. Boehringer Ingelheim International GmbH $4,717 3 payments
  7. Janssen Research & Development, LLC $4,443 6 payments
  8. E.R. Squibb & Sons, L.L.C. $3,470 2 payments
  9. Celltrion USA Inc. $2,893 3 payments
  10. Allergan Inc. $2,000 1 payment
  11. Other $2,124 49 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $61,109 40 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $4,495 2 payments
  3. Honoraria $3,900 1 payment
  4. Food and Beverage $3,064 126 payments
  5. Travel and Lodging $1,963 10 payments
  6. Grant $1,500 1 payment
  7. Education $153 5 payments
Products named General payments · program years 2019–2025
  1. REMICADE $21,504 22 payments
  2. XELJANZ $9,800 4 payments
  3. HUMIRA $5,754 27 payments
  4. Non-Covered Product $3,375 2 payments
  5. ZYMFENTRA $2,893 3 payments
  6. TREMFYA $2,799 9 payments
  7. STELARA $2,147 10 payments
  8. ZEPOSIA $1,430 1 payment
  9. SIMPONI $1,240 2 payments
  10. RINVOQ $802 45 payments
  11. Other $2,633 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $46,331 4 payments
  2. Celgene Corporation $1,925 1 payment
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,500 1 payment

Records

191 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Gastroenterology in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record